Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Cancer Metastatic × Irinotecan × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 26 Pancreatic Neoplasms 8 Colorectal Neoplasms 7 Triple Negative Breast Neoplasms 5 Stomach Neoplasms 5 Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Small Cell Lung Carcinoma 4 Breast Neoplasms, Male 4 Sarcoma 3 Rectal Neoplasms 3 Prostatic Neoplasms 3 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Colonic Neoplasms 3 Lung Neoplasms 2 Kidney Neoplasms 2 Gallbladder Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Hepatocellular 2 Bile Duct Neoplasms 2 Appendiceal Neoplasms 2 Anus Neoplasms 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Salivary Gland Neoplasms 1 Recurrence 1 Pathologic Complete Response 1

Interventions

Fulvestrant 5 Letrozole 4 exemestane 3 Capecitabine 3 Anastrozole 3 ribociclib 2 dalpiciclib 2 apatinib 2 Trastuzumab 2 Gemcitabine 2 Docetaxel 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 pyrotinib 1 patritumab deruxtecan 1 palbociclib 1 olaparib 1 nirogacestat 1 margetuximab 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Tamoxifen 1 Paclitaxel 1 Neoadjuvant Therapy 1 Liposomes 1 Irinotecan 1 Ga(III)-DOTATOC 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03328884 2025-04-23

Phenomenal

MedSIR

Phase 2 Completed

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡